Although the DOT1L did not affect the survival of ER-positive breastcancer patients who have a favourable outcome following anti-oestrogen therapy, ourclinical data support the notion that DOT1L could be a therapeutic target in moreaggressive ER-negative and metastatic human breast cancers. The gene discussed is DOT1L; the disease is breast carcinoma.